Skip to main content

Complexation of Statins with β-Cyclodextrin in Solutions of Small Molecular Additives and Macromolecular Colloids

  • Conference paper
  • First Online:
Colloids for Nano- and Biotechnology

Part of the book series: Progress in Colloid and Polymer Science ((PROGCOLLOID,volume 135))

  • 2213 Accesses

Abstract

The solubility of lovastatin and simvastatin (inevitable drugs in the management of cardiovascular diseases) was studied by phase-solubility measurements in multicomponent colloidal and non-colloidal media. Complexation in aqueous solutions of the highly lipophilic statins with β-cyclodextrin (β-CD) in the absence and the presence of dissolved polyvinyl pyrrolidone, its monomeric compound, tartaric acid and urea, respectively, were investigated. For the characterization of the CD-statin inclusion complexes, stability constants for the associates have been calculated.

It was shown that complexation might lead to considerable improvement of the aqueous solubilities of both statins. In binary systems dominantly statin-β-CD associates of 1:1 molar ratios form, which exhibit considerable surface activity.

In statin-CD-additive ternary systems the solubility of the statins could be further improved. The enhanced drug solubilities in the solutions of small molecular mass solutes are likely related due to the peculiar feature of the additives to destroy the H-bonding system of β-CD. In polymer-containing systems statin-CD-polymer associates of supramolecular structure may presumably form in a way that portions of surface-active statin-β-CD complexes are anchored at the macromolecular chains.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Prentis RA, Lis Y, Walker SR (1988) Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964–1985). Br J Clin Pharmacol 25:387–396

    CAS  Google Scholar 

  2. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160–1164

    Article  CAS  Google Scholar 

  3. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213

    CAS  Google Scholar 

  4. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, Lee HB, Cho SH (2004) Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 274:65–73

    Article  CAS  Google Scholar 

  5. Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB et al. (1994) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 74:667–673

    Article  CAS  Google Scholar 

  6. Haria M, McTavish D (1997) Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 53:299–336

    Article  CAS  Google Scholar 

  7. ME Brewster, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59:645–666

    Article  CAS  Google Scholar 

  8. Loftsson T, Brewster M (1996) Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J Pharm Sci 85(10):1017–1025

    Article  CAS  Google Scholar 

  9. Liu L, Guo QX (2002) The Driving Forces int he Inclusion Complexation of Cyclodextrins. J Incl Phenom Macrocycl Chem 42:1–14

    Article  CAS  Google Scholar 

  10. Szejtli J (1982) Cyclodextrins and Their Inclusion Complexes. Akadémiai Kiadó, Budapest, Hungary

    Google Scholar 

  11. Fenyvesi E, Vikmon M, Szeman J, Redenti E, Delcanale M, Ventura P, Szejtli J (1999) Interaction of Hydroxy Acids with β-Cyclodextrin. J Incl Phenom Macrocycl Chem 33:339–344

    Article  CAS  Google Scholar 

  12. Loftsson T, Friðriksdóttir H, Sigurðardóttir AM, Ueda H (1994) The effect of watersoluble polymers on drug-cyclodextrin complexation. Int J Pharm 110:69–177

    Article  Google Scholar 

  13. Süle A, Szente L, Csempesz F (2005) Ciklodextrinek és sztatinok kölcsönhatásának in vitro vizsgálatai. Acta Pharm Hung 75:9–13

    Google Scholar 

  14. Jun SW, Kim M-S, Kim J-S, Park HJ, Lee S, Woo J-S, Hwang S-J (2007) Preparation and characterization of simvastatin/hydroxypropyl-b-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 66:413–417

    Article  CAS  Google Scholar 

  15. Patel RP, Patel MM (2007) Physico-Chemical Characterization & In Vitro Dissolution Behavior of Simvastatin-Cyclodextrin Inclusion Compounds. Drug Deliv Technol 7(5):50–56

    CAS  Google Scholar 

  16. Higuchi T, Connors KA (1965) Phase-Solubility Techniques. Adv Anal Chem Instrum 4:117

    CAS  Google Scholar 

  17. European Directorate for the Quality of Medicines & HealthCare (EDQM) (ed) (2007) European Pharmacopeia 5th Edition 5.8 Supplement

    Google Scholar 

  18. Iga K, Hussain A, Kashihara T (1981) New direct calculation of K1:1 and K1:2 complexation constants using solubility method. J Pharm Sci 70(1):108–109

    Article  CAS  Google Scholar 

  19. Buvári-Barcza Á, Barcza L (2000) Changes in the Solubility of β-Cyclodextrin on Complex Formation: Guest Enforced Solubility of β-Cyclodextrin Inclusion Complexes. J Incl Phenom Macrocycl Chem 36:355–380

    Article  Google Scholar 

  20. Hinze WL, Pharr DY, Fu ZS, Burkert WG (1989) Thin-layer chromatography with urea-solubilized β-cyclodextrin mobile phase. Anal Chem 61:422

    Article  CAS  Google Scholar 

  21. Süle A, Csempesz F (2005) Hatóanyag-oldékonyság szabályozása ciklodextrinekkel és kolloidokkal. Abst. Semmelweis Egyetem PhD Tudományos Napok, Budapest, Hungary, p 64

    Google Scholar 

  22. Redenti E, Selva A, Pasini A, Ventura P, Casetta B (1994) Proc 7th Int Symposium on Cyclodextrins, Tokyo, p 184

    Google Scholar 

  23. Loftsson T, Stefánsson E, Friðriksdóttir H, Kristinsson JK (1996) Novel CD-based Drug Delivery System. Proc 8th Int Symposium on Cyclodextrons, pp 407–412

    Google Scholar 

  24. Pioger E, Wouessidjewe D, Douchene D, Bogdanova S (1998) Effects of Some Hydrotropic Agents on the Formation of Indomethacin/β-Cyclodextrin Inclusion Compounds. J Incl Phenom Macrocycl Chem 30:151–161

    Article  CAS  Google Scholar 

  25. Guo R, Quan S, Qian J (2004) Hydrotrope and hydrotrope-solubilization action of cephanone in CTAB/n-C5H11OH/H2O system. Colloid Polym Sci 283:15–23

    Article  CAS  Google Scholar 

  26. Stoddart FJ, Zarzycki R (1998) Cyclodextrins as second-sphere ligand for transition metal complexes. Rec Trav Chim Pays-Bas 107:515–528

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ferenc Csempesz .

Editor information

Zoltán D. Hórvölgyi Éva Kiss

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Süle, A., Csempesz, F. (2008). Complexation of Statins with β-Cyclodextrin in Solutions of Small Molecular Additives and Macromolecular Colloids. In: Hórvölgyi, Z.D., Kiss, É. (eds) Colloids for Nano- and Biotechnology. Progress in Colloid and Polymer Science, vol 135. Springer, Berlin, Heidelberg. https://doi.org/10.1007/2882_2008_120

Download citation

Publish with us

Policies and ethics